A new target for the treatment of trigeminal neuralgia with botulinum toxin type A
Authors:
- 30 October 2017
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 39 (3) , 599-602
Abstract
Trigeminal neuralgia (TN) is typically treated pharmacologically with anticonvulsants, but these can be ineffective, or can lose their effectiveness over time. In recent years, botulinum toxin type A (BoNT-A), when injected subcutaneously across multiple sites, can effectively treat TN. However, approximately 30% of TN cases are refractory to subcutaneous BoNT-A treatment. We report here the case of a 79-year-old female patient with TN presenting as severe, episodic pain in the lower left gingival area. She was on anticonvulsant therapy (carbamazepine) for about 3 years prior to BoNT-A treatment. Despite initial relief, the pain not only recurred, but also began to worsen, even as her carbamazepine dose was increased substantially. We injected 50 U of BoNT-A into the oral mucosa of the painful gingival area, but the patient’s pain was unaffected. We then changed to an intramuscular injection protocol and injected the same dose of BoNT-A into the left masseter, which produced a good therapeutic effect for about 5 months; she was then administered a second treatment (intra-masseter), and at a 2-week follow-up, still reported being pain-free. This case and a survey of the literature suggest that BoNT-A injection protocols maybe closely correlated with their clinical efficacy in cases of TN, possibly due to the ability of BoNT-A to be transported retrogradely along trigeminal nerve axons. We believe that finding the optimal BoNT-A therapy injection protocol(s) will significantly reduce the number of refractory cases of TN.Keywords
Funding Information
- National Natural Science Foundation of China (U1404809, 81571260)
This publication has 25 references indexed in Scilit:
- Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trialThe Journal of Headache and Pain, 2014
- Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-upThe Journal of Headache and Pain, 2014
- A new treatment paradigm for trigeminal neuralgia using botulinum toxin type aThe Laryngoscope, 2013
- Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trialCephalalgia, 2012
- Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin ANeuroscience, 2011
- Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary reportOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2011
- Injection of botulinum toxin type A (BOTOX) into trigger zone of trigeminal neuralgia as a means to control painOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2010
- An open study of botulinum-A toxin treatment of trigeminal neuralgiaNeurology, 2005
- Botulinum Toxin and Intractable Trigeminal NeuralgiaClinical Neuropharmacology, 2005
- Beneficial Effects of Botulinum Toxin Type A for Patients With Painful Tic ConvulsifClinical Neuropharmacology, 2002